A further analysis of data from the Phase 2 OCEAN(a)-DOSE trial has shown that olpasiran reduces Lp(a) in patients with elevated levels, irrespective of apo(a) isoform size. Small apo(a) isoforms have fewer Kringle IV-2 (KIV-2) repeats and are typically associated with higher Lp(a) concentrations compared with large apo(a) isoforms. Over 80% of people carry two different sized apo(a) isoforms, each inherited from one parent, and the smallest isoform typically predominates in plasma.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
